Erschienen in:
28.09.2023 | Pancreatic Tumors
Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis
verfasst von:
Andrew M. Fleming, MD, Leah E. Hendrick, MD, MS, Danny Yakoub, MD, PhD, Hafeez Abdelhafeez, MD, Jeremiah L. Deneve, DO, Max R. Langham Jr., MD, Evan S. Glazer, MD, PhD, Andrew M. Davidoff, MD, Nipun B. Merchant, MD, Paxton V. Dickson, MD, Andrew J. Murphy, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Abstract
Background
Pancreatic solid pseudopapillary neoplasms (SPN) are generally indolent; however, some patients present with “malignant” SPN. An orthogonal analysis of multiple datasets was performed to investigate the utility of complete surgical resection (CSR) for malignant SPN.
Methods
A systematic review was performed for cases of malignant SPN, defined as T4, N1, and/or M1. Malignant SPN was analyzed within the National Cancer Database (NCDB) and compared with T1-3N0M0 SPN. Predictors of malignant SPN were assessed, and treatments were analyzed by using survival analysis.
Results
The systematic review yielded 164 cases of malignant SPN. Of 31 children, only one died due to malignant SPN. Among adults, CSR was associated with improved disease-specific survival (DSS) (P = 0.0002). Chemotherapy did not improve malignant SPN DSS, whether resected (P = 0.8485) or not (P = 0.2219). Of 692 adults with SPN within the NCDB, 93 (13.4%) had malignant SPN. Pancreatic head location (odds ratio [OR] 2.174; 95% confidence interval [CI] 1.136–4.166; P = 0.0186) and tumor size (OR 1.154; 95% CI 1.079–1.235; P < 0.0001) associated with the malignant phenotype. Malignant SPN predicted decreased overall survival (OS) compared with T1-3N0M0 disease (P < 0.0001). Resected malignant SPN demonstrated improved OS (P < 0.0001), including resected stage IV malignant SPN (P = 0.0003). Chemotherapy did not improve OS for malignant SPN, whether resected (P = 0.8633) or not (P = 0.5734). Within a multivariable model, resection was associated with decreased hazard of death (hazard ratio 0.090; 95% CI 0.030–0.261; P < 0.0001).
Conclusions
Approximately 13% of patients with SPN present with a malignant phenotype. Pediatric cases may be less aggressive. Resection may improve survival for malignant SPN, which does not appear chemosensitive.